|Project Title||Principal Investigator||Institution|
|Biomarkers for autism and for gastrointestinal and sleep problems in autism||Anderson, George||Yale University|
|Observational and electrophysiological assessments of temperament in infants at risk for autism spectrum disorders||Burner, Karen||University of Washington|
|Early social and emotional development in toddlers at genetic risk for autism||Campbell, Susan||University of Pittsburgh|
|ACE Center: Gaze perception abnormalities in infants with ASD||Chawarska, Katarzyna||Yale University|
|Prospective study of infants at high risk for autism||Chawarska, Katarzyna||Yale University|
|Pupil size and circadian salivary variations in autism spectrum disorder||Colombo, John||University of Kansas|
|Developmental characteristics of MRI diffusion tensor pathway changes in autism||Conturo, Thomas||Washington University|
|ACE Center: MRI studies of early brain development in autism||Courchesne, Eric||University of California, San Diego|
|A longitudinal 3-D MRSI study of infants at high risk for autism||Dager, Stephen||University of Washington|
|Development of neural pathways in infants at risk for autism spectrum disorders||Dobkins, Karen||University of California, San Diego|
|Development of neural pathways in infants at risk for autism spectrum disorders (supplement)||Dobkins, Karen||University of California, San Diego|
|Are autism spectrum disorders associated with leaky-gut at an early critical period in development?||Dobkins, Karen; Schmid-Schoenbein, Geert||University of California, San Diego|
|The emergence of emotion regulation in children at-risk for autism spectrum disorder||Ekas, Naomi||University of Miami|
|Defining high and low risk expression of emotion in infants at risk for autism||Hannigen, Sarah||University of Pittsburgh|
|Misregulation of BDNF in autism spectrum disorders||Hempstead, Barbara||Weill Cornell Medical College|
|Early identification of autism: A prospective study||Iverson, Jana||University of Pittsburgh|
|Metabolic biomarkers of autism: Predictive potential and genetic susceptibility||James, Sandra||Arkansas Children's Hospital Research Institute|
|Identification of lipid biomarkers for autism||Kang, Jing||Massachusetts General Hospital|
|Model diagnostic lab for infants at risk for autism||Klin, Ami||Yale University|
|Brain-behavior growth charts of altered social engagement in ASD infants||Klin, Ami||Yale University|
|Physical and clinical infrastructure for research on infants-at-risk for autism at Yale||Klin, Ami||Yale University|
|ACE Center: Assessment Core||Klin, Ami||Yale University|
|The ontogeny of social visual engagement in infants at risk for autism||Klin, Ami||Yale University|
|ACE Center: Linguistic and social responses to speech in infants at risk for autism||Kuhl, Patricia||University of Washington|
|RNA expression studies in autism spectrum disorders||Kunkel, Louis||Children's Hospital Boston|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Identify behavioral and biological markers that separately, or in combination, accurately identify, before age 2, one or more subtypes of children at risk for developing ASD, and evaluate whether these risk markers or profiles can improve early identification through heightened developmental monitoring and screening by 2014.
IACC Recommended Budget: $33,300,000 over 5 years
|1.L.A. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 40 projects have been supported in this area, but most projects are still in the discovery phase. Identifying reliable early biomarkers has been challenging, but some progress has been made. More work is needed to achieve the full intent of the objective.
Remaining Gaps, Needs, and Opportunities: Remaining research needs include continued discovery of biomarkers, linking biomarkers to treatment response, validation of biomarkers discovered in high risk populations for applicability in the general population, and evaluation of whether these biomarkers translate to improvement in screening and diagnosis real-world settings. There is also a need for biomarkers that are cost-effective.